Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB424323 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| SB424323 | DRUG | - |
Inclusion Criteria: * Patients with non valvular atrial fibrillation and any of the following: * \</= 60 years old with no heart disease. * 60 years old with heart disease but no risk factors. * \>/=60 years old and \</=75 years old with no risk factors and no heart disease. * Must be able to take ...
SB-424323 is an investigational small molecule being studied for use in arthroplasty and in non-valvular atrial fibrillation in patients at low or intermediate risk for stroke. It is being developed by GSK plc and is currently in Phase 2 clinical development.
SB-424323 is a small molecule being studied for its potential to prevent thromboembolism. It is being evaluated in patients undergoing arthroplasty and in patients with non-valvular atrial fibrillation, where it is being tested in combination with aspirin.
SB-424323 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 2 clinical development.
SB-424323 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, one in arthroplasty and one in atrial fibrillation.
SB-424323 has been studied in two completed Phase 2 trials. The ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST, NCT00041509) enrolled 343 patients undergoing arthroplasty. A second trial (NCT00240643) enrolled 640 patients with non-valvular atrial fibrillation and evaluated SB-424323 in combination with aspirin.
No, SB-424323 is the drug being studied, while TEMPEST is the name of one of its clinical trials. The ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST, NCT00041509) is a Phase 2 study of SB-424323 in patients undergoing arthroplasty.